Danone Stock Price, News & Analysis

Danone (OTC:DANOY) has successfully launched a €1.3 billion dual-tranche bond issue. The offering consists of a €800 million 2-year floating rate notes with Euribor 3 months +27 basis points coupon and €500 million undated deeply subordinated fixed rate resettable notes with 3.95% fixed resettable coupon and first call date on September 8, 2032.

The proceeds will be used for general corporate purposes, with the subordinated notes refinancing existing €500 million notes callable in September 2026. The settlement is expected on September 8, 2025, with listing on Euronext Paris. The undated subordinated notes will be treated as full equity under IFRS and 50% equity by rating agencies.

Danone (OTC:DANOY) has released its monthly update on total shares and voting rights as of July 31, 2025. The company reported a total of 681,394,483 shares outstanding. The total number of theoretical voting rights stands at 721,744,530, while exercisable voting rights amount to 684,201,719.

This disclosure is made in compliance with French regulatory requirements, specifically Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation.

Danone (OTC:DANOY) has announced a significant organizational restructuring effective January 1st, 2026, as part of its Renew transformation strategy. The company will streamline operations into three geographical divisions: EMEA (under Pablo Perversi), Asia Pacific (under Bruno Chevot), and Americas (under Henri Bruxelles), all reporting to Group Deputy CEO Véronique Penchienati-Bosetta.

The reorganization aims to enhance market impact and agility. Christian Stammkoetter, current President for Asia, Africa and the Middle East, will depart after 19 years with the company. Additionally, Laurent Sacchi, General Secretary, will take over leadership of Sustainability initiatives.

Danone, which generated €27.4 billion in sales in 2024, operates in three health-focused categories: Essential Dairy & Plant-Based products, Waters, and Specialized Nutrition, with products sold in over 120 markets worldwide.

Danone (OTC:DANOY) has announced the release of its 2025 interim financial report for the period ending June 30, 2025. The half-year financial report is now accessible to investors and stakeholders through the company's website.

Danone (OTC:DANOY) reported strong H1 2025 results with sales reaching €13,737 million, up +4.2% like-for-like, driven by volume/mix growth of +2.6% and price increase of +1.7%. The company's recurring operating margin expanded by 49 basis points to 13.2%, while recurring EPS grew +5.8% to €1.91.

Key highlights include strong performance in Specialized Nutrition (+7.0% LFL) and significant growth in China, North Asia & Oceania region (+11.3% LFL). The company completed strategic acquisitions including Kate Farms, the #1 doctor-recommended plant-based brand in the U.S., and The Akkermansia Company in the biotics sector.

Danone confirmed its 2025 guidance, projecting like-for-like sales growth between +3% and +5%, with recurring operating income growing faster than sales.

Danone (OTC:DANOY) has released its monthly report on total shares and voting rights as of June 30, 2025. The company reported a total of 681,394,483 shares outstanding, with 721,120,820 theoretical voting rights and 683,024,152 exercisable voting rights.

This disclosure is made in compliance with French regulatory requirements, specifically Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. The difference between theoretical and exercisable voting rights reflects shares with suspended voting rights.

Danone (OTC:DANOY) has successfully completed the acquisition of a majority stake in Kate Farms, the leading doctor-recommended plant-based nutrition brand in the United States. The strategic acquisition enhances Danone's specialized nutrition portfolio in North America by combining Kate Farms with its existing brands Nutricia, Real Food Blends, and Functional Formularies.

Brett Matthews, former CEO and Chairman of Kate Farms, will serve as Chairman and CEO of the combined business effective immediately. The integration aims to expand access to specialized nutrition across various channels including hospitals, homes, online platforms, and retail shelves.

Kate Farms, founded to address a critical need for allergen-free tube feeding formula, has grown to become a major player in the specialized nutrition space with products available in over 1,400 U.S. hospitals. The company's products are eligible for insurance coverage through Medicare, Medicaid, private insurance, and WIC in 33+ states. This acquisition aligns with Danone's Renew strategy and builds upon its existing €27.4 billion in sales reported for 2024.

[ "Acquisition strengthens Danone's position in the U.S. specialized nutrition market", "Integration combines #1 doctor-recommended plant-based brand with Danone's existing nutrition portfolio", "Expanded distribution network across 1,400+ U.S. hospitals", "Strong insurance coverage including Medicare, Medicaid, and WIC in 33+ states", "Retention of successful Kate Farms management team ensures continuity" ]

Danone (OTC:DANOY) has announced the acquisition of The Akkermansia Company (TAC), a Belgian biotic specialist with nearly 20 years of expertise. TAC is known for its groundbreaking 2004 discovery of Akkermansia muciniphila MucT™, a biotic strain clinically proven to strengthen gut barriers, reduce inflammation, and combat metabolic disorders including obesity, diabetes, and cardiovascular disease.

This strategic acquisition aligns with Danone's Renew strategy, emphasizing scientific innovation and responding to growing consumer demand for health-focused products. The company, which generated €27.4 billion in sales in 2024, operates across three health-focused categories: Essential Dairy & Plant-Based products, Waters, and Specialized Nutrition, with products available in over 120 markets globally.

Danone (DANOY) has disclosed its latest share and voting rights data as of May 31, 2025. The company reported a total of 681,068,400 shares outstanding. The total number of theoretical (gross) voting rights stands at 718,099,987, while the exercisable (net) voting rights amount to 680,003,319. This disclosure is in compliance with French regulatory requirements, specifically Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. The difference between theoretical and exercisable voting rights indicates shares with suspended voting rights.